Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation

Molecular Immunology

Volumn 39, Issue 17-18, 2003, Pages 1083-1088

  Abou Jaoude, Maroun M ^a   Ghantous, Imad ^a   Almawi, Wassim Y ^b  

^a SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

^b ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

ATG F; Daclizumab; Interleukin 2 receptor; Kidney transplantation (KT)

Indexed keywords

CREATININE; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; BACTERIAL INFECTION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; VIRUS INFECTION;

BACTERIA (MICROORGANISMS);

EID: 0038094500     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(03)00072-5     Document Type: Conference Paper

References (24)

1. Brock M.V., Borja M.C., Ferber L., Orens J.B., Anzcek R.A., Krishnan J., Yang S.C., Conte J.V. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J. Heart Lung Transplant. 20:2001;1282-1290.
2. Bumgardner G.L., Ramos E., Lin A., Vincenti F. Daclizumab (humanized anti-IL-2Rα mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation. 72:2001;642-647.
3. Carswell C.I., Plosker G.L., Wagstaff A.J. Daclizumab: a review of its use in the management of organ transplantation. BioDrugs. 15:2001;745-773.
4. Ekberg H., Backman L., Tufveson G., Tyden G., Nashan B., Vincenti F. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl. Int. 13:2000;151-159.
5. Emre S., Gondolesi G., Polat K., Ben-Haim M., Artis T., Fishbein T.M., Sheiner P.A., Kim-Schluger L., Schwartz M.E., Miller C.M. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl. 7:2001;220-225.
6. Ferguson R.M. A multicenter experience with sequential ALG/cyclosporine therapy in renal transplantation. Clin. Transpl. 2:1988;285-291.
7. Garrity E.R. Jr., Villanueva J., Bhorade S.M., Husain A.N., Vigneswaran W.T. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation. 71:2001;773-777.
8. Goebel J., Stevens E., Forrest K., Roszman T.L. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl. Immunol. 8:2000;153-159.
9. Horl M.P., Schmitz M., Ivens K., Grabensee B. Opportunistic infections after renal transplantation. Curr. Opin. Urol. 12:2002;115-123.
10. Humar A., Ramcharan T., Denny R., Gillingham K.J., Payne W.D., Matas A.J. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation. 72:2001;1920-1923.
11. Martins L., Henriques A.C., Dias L., Sarmento A.M., Pereira M.C., Guimaraes S. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results. Transplant. Proc. 32:2000;2623-2625.
12. Massy Z.A., Guijarro C., Wiederkehr M.R., Ma J.Z., Kasiske B.L. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int. 49:1996;518-524.
13. Morris, R.E., 1996. Mechanisms of action of immunosuppressive drugs. Kidney Int. Suppl. 53, S26-S38.
14. Morris J.C., Waldmann T.A. Advances in interleukin 2 receptor targeted treatment. Ann. Rheum. Dis. 59(Suppl. 1):2000;i109-i114.
15. Moser M.A. Options for induction immunosuppression in liver transplant recipients. Drugs. 62:2002;995-1011.
16. Moudgil A., Vo A., Toyoda M., Jordan S.C. Daclizumab is comparable to anti-thymocyte globulin (ATG) induction in preventing acute rejection (AR) episodes in high risk renal transplant patients. Transplantation. 67:1999;S151.
17. Nashan B., Light S., Hardie I.R., Lin A., Johnson J.R. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation. 67:1999;110-115.
18. Rasaiah S.B., Light J.A., Sasaki T.M., Currier C.B. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression. Clin. Transpl. 14:2000;409-412.
19. Schroeder T.J., Weiss M.A., Smith R.D., Stephens G.W., First M.R. The efficacy of OKT3 in vascular rejection. Transplantation. 51:1991;312-315.
20. Sims T.W., Good E.W. The next generation of medications for kidney transplant patients. Crit. Care Nurs. Clin. N. Am. 14:2002;99-109.
21. Tejani A., Emmett L. Acute and chronic rejection. Semin. Nephrol. 21:2001;498-507.
22. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., Neylan J., Wilkinson A., Ekberg H., Gaston R., Backman L., Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N. Engl. J. Med. 338:1998;161-165.
23. Vincenti F., Grinyo J., Ramos E., Nashan B., Stuart F., Kuypers D., Brattstrom C., Cho S., Ekberg H., Johnson R. Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant. Proc. 31:1999;1246-1248.
24. Waldmann T.A. T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma. Ann. Oncol. 11(Suppl. 1):2000;101-106.